Specialty Pharmacy

In an interview with Specialty Pharmacy Times, former NFL placekicker, Rolf Benirschke, CEO of Legacy Health Strategies, discusses why an effective communication channel is critical to achieving optimal outcomes for patients with IBD.

In an interview with Specialty Pharmacy Times, former NFL placekicker, Rolf Benirschke, CEO of Legacy Health Strategies, discusses how pharmacists can be there when counseling a patient who may have IBD or Crohen disease.

Research adds to a previously found correlation between yogurt consumption and a lowered risk of bowel cancer.

Patients with psoriasis reported frequent use of complementary and alternative treatments when their initial therapies did not help or had adverse effects.

American Society of Health-System Pharmacists summer meeting included topics tied to the overarching themes of health system specialty pharmacy operations, clinical outcomes, and business development

Top news of the day from across the health care landscape.

Tofacitinib shows promising results in adult patients with moderately to severely active rheumatoid arthritis as a monotherapy with or without methotrexate.

There are currently an estimated 8.1 million males and 8.8 million females in the United States with a history of cancer.

A protein called DDX3X has been found to regulate a melanoma-specific oncogene called MITF that is central to the development of the pigment cells in the skin.

Top news of the day from across the health care landscape.

A recent study analyzed the 10-year absolute risks of thromboembolism and bleeding in patients with a history of hematologic cancer.

Top news of the day from across the health care landscape.

A new study of patients treated with ophthalmology medications indicates that electronic health records may not contain accurate, up-to-date information.

CDc11+ dendritic cells are the first to interact with HIV and transmit the virus to other cells in the body.

This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings, and more. Our Week in Review is a can't miss for the busy pharmacy professional.

Patients with psoriasis reported frequent use of complementary or alternative medicine, but less than half said they would recommend these therapies to others.

As young patients with bone cancer are often treated with high doses of chemotherapy before and after surgery, researchers wanted to develop gentler treatment options.

Selinexor (Xpovio, Karyopharm) received approval in combination with dexamethasone for heavily-pretreated patients with relapsed or refractory multiple myeloma.

Three new studies looked at the mechanisms involved in tissue damage related to rheumatoid arthritis and lupus.

FOXA1 has been previously known to be mutated in prostate cancer; however, its biological functions were not understood well.

Top news of the day from across the health care landscape.

Aptevo Therapeutics announced the launch of its new vial size for its coagulation factor IX recombinant (Ixinity) treatment for hemophilia B in the US market.

A recent study showed that adherence to prophylaxis for severe hemophilia A can improve a patient’s physical performance.

Top news of the day from across the health care landscape.

Specific types of cancer—such as bone, kidney, throat, and uterine—also had a higher incidence of chronic and severe pain that restricted daily activity.

Treatment with secukinumab (Cosentyx, Novartis) inhibited radiographic progression in most patients with psoriatic arthritis over 2 years in a phase 3 trial.

Top news of the day from across the health care landscape.

Officials with the FDA have approved a new enteric-coated formulation of tiopronin (Thiola EC, Retrophin) 100 mg and 300 mg tablets, for the treatment of cystinuria.

Technology solutions such as CourMed will allow better pharmacist-patient communication, adherence, and overall improved patient outcomes.

Pfizer’s bevacizumab-bvzr (Zirabev) demonstrated clinical equivalence and no clinically meaningful differences compared with the reference product.